Invesco Ltd. Acquires Shares of 49,947 Takeda Pharmaceutical Co. $TAK

Key Points

• Invesco Ltd. purchased nearly 50,000 shares of Takeda Pharmaceutical Co. valued at approximately $743,000 during the first quarter.
• Institutional investors collectively own 9.17% of Takeda's stock, with Charles Schwab and other firms increasing their stakes significantly.
• Takeda Pharmaceutical has seen a change in analyst ratings, with Zacks Research downgrading the stock from a "hold" to a "strong sell" rating.

Invesco Ltd. purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 49,947 shares of the company's stock, valued at approximately $743,000.

Other large investors also recently made changes to their positions in the company. Vise Technologies Inc. increased its stake in shares of Takeda Pharmaceutical by 3.1% in the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock worth $459,000 after purchasing an additional 1,026 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Takeda Pharmaceutical by 5.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock valued at $319,000 after purchasing an additional 1,098 shares during the last quarter. Allworth Financial LP lifted its position in Takeda Pharmaceutical by 12.7% during the first quarter. Allworth Financial LP now owns 10,797 shares of the company's stock valued at $163,000 after purchasing an additional 1,215 shares during the last quarter. Finally, Choreo LLC lifted its holdings in shares of Takeda Pharmaceutical by 6.1% in the 1st quarter. Choreo LLC now owns 21,262 shares of the company's stock worth $316,000 after acquiring an additional 1,229 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Up 0.7%

NYSE:TAK traded up $0.11 during midday trading on Friday, reaching $15.40. 3,326,096 shares of the stock traded hands, compared to its average volume of 2,709,035. The company has a fifty day moving average of $14.83 and a 200 day moving average of $14.78. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.56. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The stock has a market capitalization of $48.99 billion, a P/E ratio of 51.32 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, research analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.